Tuesday, July 13, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)

A Conversation with the Investigators: Chimeric Antigen Receptor T-Cell Therapy in Hematologic Cancers

A Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual Meeting

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.


Join us on Tuesday, July 13th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty

Caron Jacobson, MD
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

David G Maloney, MD, PhD
Professor, Clinical Research Division
Medical Director, Cellular Immunotherapy
Leonard and Norma Klorfine Endowed Chair for Clinical Research
Fred Hutchinson Cancer Research Center
Professor of Medicine, Division of Oncology
University of Washington
Medical Director
Cellular Immunotherapy and Bezos Family Immunotherapy Clinic
Seattle Cancer Care Alliance
Seattle, Washington

Nikhil C Munshi, MD
Kraft Family Chair
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

This activity is supported by educational grants from Bristol-Myers Squibb Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Diffuse Large B-Cell Lymphoma (DLBCL)

  • Biologic rationale for targeting CD19 with chimeric antigen receptor (CAR) T-cell therapy for lymphoma; overview of CAR T-cell therapy
  • Clinical factors (eg, age, preexisting comorbidities, symptomatology, performance status) in the selection of CAR T-cell therapy for patients with DLBCL; timing of administration
  • Design and entry criteria for the ZUMA-1, JULIET and TRANSCEND NHL 001 trials supporting the FDA approvals of axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel, respectively; proportion of trial participants who underwent apheresis and eventually received CAR T-cell therapy
  • Similarities and differences among the available CD19-directed CAR T-cell therapies for DLBCL
  • Updated results from the Phase II JULIET trial of tisagenlecleucel for relapsed/refractory (R/R) DLBCL; patient-reported long-term quality-of-life outcomes
  • Key efficacy and safety findings supporting the recent FDA approval of lisocabtagene maraleucel for R/R DLBCL (TRANSCEND NHL-001); patient selection for use in routine clinical practice
  • Predictors of response, if any, to CAR T-cell therapy in DLBCL; factors predicting early disease progression after CAR T-cell therapy
  • Real-world outcomes with commercial CAR T-cell therapies for patients with DLBCL after disease progression on at least 2 prior lines of systemic therapy in comparison to other treatment options (eg, platinum-based regimens, bendamustine/rituximab, lenalidomide/rituximab, ibrutinib)
  • Clinical role and utility of CAR T-cell therapies for DLBCL in light of the recent FDA approvals of the CD19-directed antibodies loncastuximab tesirine and tafasitamab for patients with R/R DLBCL
  • Interim results from the Phase II ZUMA-12 trial of axicabtagene ciloleucel as first-line therapy for patients with high-risk large B-cell lymphoma; potential role of CAR T-cell therapy in the first-line setting
  • Spectrum, frequency, timing and severity of adverse events associated with anti-CD19 CAR T-cell therapies, including cytokine release syndrome and neurologic toxicities; effective management strategies
  • Selection and appropriate referral of patients with DLBCL for consideration of CAR T-cell therapy
  • Ongoing studies evaluating novel CAR T-cell therapy-based approaches (eg, acalabrutinib/axicabtagene ciloleucel) for patients with DLBCL (eg, PORTIA, TRANSFORM, TRANSCENDWORLD trials)

Other Lymphoma Subtypes and Leukemia

  • Efficacy and safety of tisagenlecleucel for adults with R/R follicular lymphoma (ELARA trial); significance of the FDA regenerative medicine advanced therapy designation
  • Key efficacy and safety findings from the ZUMA-5 trial supporting the recent FDA approval of axicabtagene ciloleucel for patients with R/R follicular lymphoma
  • Data supporting the recent FDA approval of lisocabtagene maraleucel for patients with R/R Grade IIIB follicular lymphoma (TRANSCEND NHL-001 trial); role in clinical practice
  • Factors guiding the selection of patients with R/R follicular lymphoma for treatment with tisagenlecleucel, axicabtagene ciloleucel or lisocabtagene maraleucel
  • Rationale for the evaluation of brexucabtagene autoleucel, an anti-CD19 CAR T-cell therapy, for patients with mantle-cell lymphoma
  • Data from the Phase II ZUMA-2 trial supporting the FDA approval of brexucabtagene autoleucel for patients with R/R mantle-cell lymphoma; optimal incorporation into practice
  • Initial safety and efficacy results from the ongoing Phase I/II TRANSCEND CLL 004 trial evaluating lisocabtagene maraleucel for R/R chronic lymphocytic leukemia; potential clinical role
  • FDA approval of tisagenlecleucel for pediatric and young adult patients with acute lymphocytic leukemia (ALL) that is refractory or in second or later relapse; ongoing clinical investigation of CAR T-cell therapy in the adult population
  • Results from the Phase II ZUMA-3 study evaluating brexucabtagene autoleucel for patients with R/R B-cell ALL
  • Other promising ongoing trials evaluating CAR T-cell therapies for B-cell non-Hodgkin lymphoma (eg, BELINDA), chronic lymphocytic leukemia (eg, ZUMA-8) and ALL (eg, ZUMA-4)

Multiple Myeloma (MM)

  • Biologic rationale for targeting the B-cell maturation antigen (BCMA) with CAR T-cell therapy for MM
  • Compositional and mechanistic similarities and differences among various BCMA-targeted CAR T-cell platforms under investigation for MM
  • Design, eligibility criteria and available efficacy and safety results from the pivotal Phase II KarMMa trial of idecabtagene vicleucel for patients with R/R MM; recent FDA approval and optimal integration into treatment algorithms
  • Clinical, biologic and pathologic factors in the selection of patients with MM for treatment with CAR T-cell therapy
  • Updated results from the CARTITUDE-1, EVOLVE and CRB-402 trials of ciltacabtagene autoleucel, orvacabtagene autoleucel and bb21217, respectively, for patients with R/R MM
  • Incidence, timing and severity of adverse events associated with BCMA-directed CAR T-cell therapies for MM; optimal monitoring and management strategies
  • Other promising CAR T-cell platforms under investigation in MM (eg, CC-98633, MCARH109)

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of chimeric antigen receptor (CAR) T-cell therapy.

Learning Objectives

  • Develop an understanding of the scientific rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences among commercially available and investigational products.
  • Recognize available efficacy and safety data with the use of CAR T-cell therapies directed at CD19, and effectively integrate this novel strategy into the treatment of relapsed/refractory (R/R) B-cell lymphomas.
  • Consider the recent FDA approval of the anti-CD19 CAR T-cell therapy brexucabtagene autoleucel for R/R mantle cell lymphoma, and identify patients for whom treatment with this agent might be beneficial.
  • Evaluate the biologic basis for the investigation of CAR T-cell therapy for R/R follicular lymphoma (FL) and chronic lymphocytic leukemia, and educate patients about the potential clinical role of this strategy.
  • Discuss the recent FDA approval of lisocabtagene maraleucel, a CAR T-cell therapy targeting CD19, for patients with R/R large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and Grade IIIB FL.
  • Appreciate available research findings supporting the recent FDA approval of the anti-CD19 CAR T-cell therapy axicabtagene ciloleucel for patients with R/R FL.
  • Appraise the scientific rationale for and available data with the use of CAR T-cell therapy directed at the B-cell maturation antigen (BCMA) in the care of patients with multiple myeloma (MM), and assess the similarities and differences among the various investigational approaches.
  • Recognize the recent FDA approval of the anti-BCMA CAR T-cell therapy idecabtagene vicleucel for R/R MM, and use this knowledge to identify patients who may be appropriate for a clinical trial of this approach.
  • Identify common adverse events associated with FDA-approved and investigational CAR T-cell therapies, and implement strategies to educate patients and manage complications.
  • Recall ongoing research evaluating CAR T-cell therapy approaches for various B-cell lymphomas, chronic lymphocytic leukemia and MM, and counsel appropriate patients regarding the potential benefits of trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Bristol-Myers Squibb Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.